Scientists at a lab in Stanford Medicine have discovered a naturally-produced molecule that seems to decrease the desire to eat and facilitate weight loss – in the same way as weight-loss medications like Ozempic – but the molecule does not cause digestive complaints that are commonly tied to drug therapy. This finding has been described as a “measured excitation” by researchers who have always been looking out for “safer” ways for obesity and related metabolic conditions to be handled. The molecule seems to act in a way with the body processes that signal the brain you want to eat. Early stage studies on lab models and mice, that were done by scientists, showed that the amount of food consumed was reduced and that the weight of test subjects had dropped without their becoming ill or vomiting in response to the molecule as it happened in GLP-1 receptor agonist patients with side effects.
Scientists who are working with the development described the compound as something of the body’s own, which is produced in small amounts. If that assumption is correct, the substance could be used by the body in a natural state without making the individual’s system work extra. The fact of a natural replacement for weight-loss injectables like semaglutide is attractive for the millions of people who have tried these medications or were thinking to take them. Users of currently available weight-loss injectables say they achieve desired weight loss but on the flip side often complain of side effects that affect their life, and some users have discontinued treatment due to these. And, others express their concern about the side effects of these medication if used long term and it is still under a study phase.
There are several ways to interpret it, but really it is a molecule with natural background showing similar benefits but also with less tolerability issue, which makes patients feel good enough to follow it if research supports that it is safe to continue taking them. The compound that is of interest for the research group at Stanford was identified with the help of cutting-edge screen and artificial intelligence techniques. Once they had a candidate substance which was to be tested for effects on control of appetite and markers for metabolism, they did a test which was successful in showing a decline in intake of calories without causing an abrupt slowing of digestion which was the cause of discomfort for patients using therapies that were already available.
The authors admit that these are early findings and human trials have not yet started. It is quite often that laboratory research findings fail to be a basis for development of new medicines. But, at present, the discovery of the new compound is timed right when demand for weight-loss methods is going up all over. Although obesity rates are still very high in several parts of the world, they are a contributing factor to diabetes, heart disease, and decreased life quality. Medications are already causing a model shift by assisting patients in losing lots of weight and even maintaining it over time. Providing patients with different choices so that fewer patients stop their treatment due to side effects will be a major achievement. Some other experts commented the new molecule with reservation. They have mentioned that the pathway targeted by the drug is the same one as the GLP-1 drugs do, which is a reason for appetite suppression to be quite similar in both. But at the same time, the absence of some side effects in preliminary trials indicates that the mechanism of action could be different to GLP-1 or the molecule is just more specific. The next phase should clarify what is actually happening – whether is a matter of safety and tolerability with high doses or a matter of developing the right ways of administering the drug and understanding how it behaves in people with different metabolic states.
Alongside weight loss, the researchers wonder if the compound would have other metabolic health benefits like better regulation of blood sugar and less inflammation. Beyond weight loss, researchers are curious whether the compound might offer additional metabolic benefits, like improved blood sugar control or reduced inflammation. Those questions will take years to answer.
